Clinical Trial

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, randomized, controlled phase II study evaluating induction immuno-chemotherapy and concurrent chemoradiotherapy with or without apatinib in unresectable, locally advanced esophageal squamous cell carcinoma
Protocol Amendment History 3 changes
critical Trial completed 2026-08-04
notable Primary completion moved earlier: 2026-12-01 -> 2026-06-25 2026-08-04
minor Completion moved earlier: 2026-12-01 -> 2026-06-25 2026-08-04
Trial Details
NCT Number NCT06281886
Lead Sponsor Sun Yat-sen University
Conditions Esophageal Squamous Cell Carcinoma, Efficacy, Toxicity
Enrollment 170 participants
Start Date 2024-02-15
Primary Completion 2026-06-25 (estimated)
Study Completion 2026-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-03